HemaSense has successfully secured $630,000 in investment capital to accelerate the development and market readiness of its innovative medical device. This funding round marks a pivotal step for the company as it progresses its mission to enhance patient safety and operational efficiency in post-operative care.
The company is dedicated to improving patient outcomes and reducing costs associated with percutaneous interventions. HemaSense achieves this by providing healthcare professionals with the first early alert system specifically designed for bleeding complications at the access site during post-operative recovery. Its core product is an access site monitor that seamlessly integrates into existing patient recovery workflows. This monitor provides early detection and alerts of subcutaneous bleeding events, enabling healthcare providers to intervene promptly and less costly when small amounts of blood begin to accumulate outside the femoral vessel.
This significant capital infusion will primarily be allocated to further research and development efforts, advancing the HemaSense monitor's capabilities and supporting the necessary steps for eventual market entry. The investment underscores investor confidence in HemaSenseโs proprietary technology and its potential to address an unmet clinical need in managing post-procedural complications.
The $630,000 in raised funds is expected to bolster the company's operational capacity, facilitate crucial product testing, and enable strategic hires to expand the engineering and clinical support teams. HemaSense plans to leverage this investment to solidify its technological foundation and prepare for the next phase of growth, focusing on commercialization strategies to bring its life-improving technology to a broader patient population and healthcare providers.
